SCHEDULE: Amova Asset Management Discloses 4.7% Stake in 10x Genomics

Amova Asset Management Americas, Inc. has filed an amendment to its Schedule 13G, reporting a 4.7% beneficial ownership stake in 10x Genomics, Inc. as of September 30, 2025.

Summary

• Amova Asset Management Americas, Inc. (formerly Nikko Asset Management Americas, Inc.) filed an Amendment No. 1 to its Schedule 13G.
• The filing reports beneficial ownership of Class A common stock of 10x Genomics, Inc.
• As of September 30, 2025, Amova Asset Management Americas, Inc. beneficially owned 5,376,883 shares.
• This represents 4.7% of the Class A common stock of 10x Genomics, Inc.
• The reporting person has shared voting power over 5,009,111 shares and shared dispositive power over 5,376,883 shares.
• Amova Asset Management Americas, Inc. is classified as an investment adviser.
• Parent holding companies include Sumitomo Mitsui Trust Group Inc. and Amova Asset Management Co., Ltd. (formerly Nikko Asset Management Co., Ltd.).

Sentiment

Score: 5

Explanation: The filing is a standard regulatory disclosure of beneficial ownership, indicating a passive investment. It does not contain information that would inherently suggest positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

NA

Industry Context

This filing reflects a passive investment position by an asset management firm in a biotechnology tools company. Such disclosures are routine for institutional investors and provide transparency into significant holdings within the industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holding, which can influence market perception and liquidity.

Key Dates

Keywords

10x Genomics, Amova Asset Management, Schedule 13G, Beneficial Ownership, Investment Adviser, Class A Common Stock, Sumitomo Mitsui Trust Group